 WATERTOWN, Mass., June 01, 2022 GLOBE NEWSWIRE -- Kymera Therapeutics, Inc. NASDAQ: KYMR, a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will present new preclinical data demonstrating that STAT3 degradation blocked Th17 development and cytokine release and prevented collagen-induced arthritis CIA, a pre-clinical model of rheumatoid arthritis, today at the EULAR 2022 Congress in Copenhagen, Denmark. 